931 related articles for article (PubMed ID: 35951774)
21. Gut Commensal
Lai CH; Lin TL; Huang MZ; Li SW; Wu HY; Chiu YF; Yang CY; Chiu CH; Lai HC
Front Immunol; 2022; 13():916848. PubMed ID: 35844600
[No Abstract] [Full Text] [Related]
22. Innate and adaptive immunity in inflammatory bowel disease.
Geremia A; Biancheri P; Allan P; Corazza GR; Di Sabatino A
Autoimmun Rev; 2014 Jan; 13(1):3-10. PubMed ID: 23774107
[TBL] [Abstract][Full Text] [Related]
23. Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans.
Wang ZJ; Chen XF; Zhang ZX; Li YC; Deng J; Tu J; Song ZQ; Zou QH
Microb Pathog; 2017 Aug; 109():156-161. PubMed ID: 28552806
[TBL] [Abstract][Full Text] [Related]
24. Effects of sodium butyrate supplementation on inflammation, gut microbiota, and short-chain fatty acids in Helicobacter pylori-infected mice.
Huang Y; Ding Y; Xu H; Shen C; Chen X; Li C
Helicobacter; 2021 Apr; 26(2):e12785. PubMed ID: 33609322
[TBL] [Abstract][Full Text] [Related]
25. Association between intestinal microbiome and inflammatory bowel disease: Insights from bibliometric analysis.
Xu P; Lv T; Dong S; Cui Z; Luo X; Jia B; Jeon CO; Zhang J
Comput Struct Biotechnol J; 2022; 20():1716-1725. PubMed ID: 35495114
[TBL] [Abstract][Full Text] [Related]
26. Causality of small and large intestinal microbiota in weight regulation and insulin resistance.
Scheithauer TP; Dallinga-Thie GM; de Vos WM; Nieuwdorp M; van Raalte DH
Mol Metab; 2016 Sep; 5(9):759-70. PubMed ID: 27617199
[TBL] [Abstract][Full Text] [Related]
27. The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy.
Oduro PK; Zheng X; Wei J; Yang Y; Wang Y; Zhang H; Liu E; Gao X; Du M; Wang Q
Acta Pharm Sin B; 2022 Jan; 12(1):50-75. PubMed ID: 35127372
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
[TBL] [Abstract][Full Text] [Related]
29. The impact of probiotics on gut microbiota in the eradication of Helicobacter pylori infection: a systematic review.
Bai XF; Tian D; Wang TY; Shu JC; He YJ; Zhu MJ
Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6736-6743. PubMed ID: 37522685
[TBL] [Abstract][Full Text] [Related]
30. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity.
Remely M; Aumueller E; Merold C; Dworzak S; Hippe B; Zanner J; Pointner A; Brath H; Haslberger AG
Gene; 2014 Mar; 537(1):85-92. PubMed ID: 24325907
[TBL] [Abstract][Full Text] [Related]
31. The interaction of bile acids and gut inflammation influences the pathogenesis of inflammatory bowel disease.
Di Ciaula A; Bonfrate L; Khalil M; Portincasa P
Intern Emerg Med; 2023 Nov; 18(8):2181-2197. PubMed ID: 37515676
[TBL] [Abstract][Full Text] [Related]
32. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota.
Chen ML; Yi L; Zhang Y; Zhou X; Ran L; Yang J; Zhu JD; Zhang QY; Mi MT
mBio; 2016 Apr; 7(2):e02210-15. PubMed ID: 27048804
[TBL] [Abstract][Full Text] [Related]
33. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.
Sharma M; Mitnala S; Vishnubhotla RK; Mukherjee R; Reddy DN; Rao PN
J Clin Exp Hepatol; 2015 Jun; 5(2):147-58. PubMed ID: 26155043
[TBL] [Abstract][Full Text] [Related]
34. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
35. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
36. ESRRA (estrogen related receptor alpha) is a critical regulator of intestinal homeostasis through activation of autophagic flux via gut microbiota.
Kim S; Lee JY; Shin SG; Kim JK; Silwal P; Kim YJ; Shin NR; Kim PS; Won M; Lee SH; Kim SY; Sasai M; Yamamoto M; Kim JM; Bae JW; Jo EK
Autophagy; 2021 Oct; 17(10):2856-2875. PubMed ID: 33172329
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota-a double-blind, placebo-controlled, randomized trial.
Chen MJ; Chen CC; Huang YC; Tseng CC; Hsu JT; Lin YF; Fang YJ; Wu MS; Liou JM;
Helicobacter; 2021 Dec; 26(6):e12857. PubMed ID: 34708471
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapeutic Drugs Induce Different Gut Microbiota Disorder Pattern and NOD/RIP2/NF-κB Signaling Pathway Activation That Lead to Different Degrees of Intestinal Injury.
Huang B; Gui M; Ni Z; He Y; Zhao J; Peng J; Lin J
Microbiol Spectr; 2022 Dec; 10(6):e0167722. PubMed ID: 36222691
[TBL] [Abstract][Full Text] [Related]
39. The gut microbiota - A vehicle for the prevention and treatment of hepatocellular carcinoma.
Beyoğlu D; Idle JR
Biochem Pharmacol; 2022 Oct; 204():115225. PubMed ID: 35998677
[TBL] [Abstract][Full Text] [Related]
40. Intestinal Inflammation and Altered Gut Microbiota Associated with Inflammatory Bowel Disease Render Mice Susceptible to Clostridioides difficile Colonization and Infection.
Abernathy-Close L; Barron MR; George JM; Dieterle MG; Vendrov KC; Bergin IL; Young VB
mBio; 2021 Jun; 12(3):e0273320. PubMed ID: 34126769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
